What’s the full story? Leerink anticipates upward pressure on consensus expectations for Cobenfy (KarXT) and milvexian, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback